Not available
Quote | Miragen Therapeutics Inc. (NASDAQ:MGEN)
Last: | $23.01 |
---|---|
Change Percent: | -0.09% |
Open: | $23.29 |
Close: | $23.01 |
High: | $23.9 |
Low: | $22.9701 |
Volume: | 44,316 |
Last Trade Date Time: | 01/19/2021 04:56:03 pm |
News | Miragen Therapeutics Inc. (NASDAQ:MGEN)
miRagen Therapeutics (MGEN) announced its name change to Viridian Therapeutics and ticker symbol 'VRDN'; to commence trading tomorrow.The company appointed Jonathan Violin, Ph.D., M.B.A. as President and CEO succeeding Lee Rauch who will remain as strategic advisor to the company; D...
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye disease Company recently licensed exc...
Message Board Posts | Miragen Therapeutics Inc. (NASDAQ:MGEN)
Subject | By | Source | When |
---|---|---|---|
This is moving Possible buyout coming. Allot of | CryptoWStreet | investorshub | 01/07/2021 9:42:56 PM |
Nice pop this morning | Nickwvt | investorshub | 11/17/2020 3:11:57 PM |
It was a R/S. | AW104 | investorshub | 11/15/2020 1:45:45 PM |
I am kicking myself in the ass on | Origen_Adamantius | investorshub | 11/13/2020 8:25:19 PM |
I know its dead air here. They anounce | Dusty18 | investorshub | 11/10/2020 10:51:43 PM |
News, Short Squeeze, Breakout and More Instantly...
Miragen Therapeutics Inc. Company Name:
MGEN Stock Symbol:
NASDAQ Market:
Miragen Therapeutics Inc. Website:
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye disease Company recently licensed exc...
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRD...
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance mult...